Breakthrough technologies to treat complex oncolytic and neurological conditions

Our Technologies

Alcyone Lifesciences Announces Research Collaboration with a Leading Biopharmaceutical Company to Improve Intrathecal Delivery of Therapies for Rare and Orphan Neurological Conditions

Mission

At Alcyone, we are committed to developing biologically inspired and clinically relevant solutions to significantly enhance current treatment modes for patients suffering from oncolytic and chronic neurological conditions.

About Alcyone

Our Therapeutic Focus Oncology & Neuroscience

Learning Center

Our Technologies

Alcyone MEMS Cannula (AMC™)*

Alcyone technologies for chronic neuropathological conditions

Intrathecal Delivery**

Pulsar CSF Dynamic Intrathecal System by Alcyone Lifesciences

All Technologies

Upcoming Conferences & Events

Boston, MA

October 29th – 30th, 2018
TBD

*Alcyone previously sponsored the 2017 ICCS/SRHSB Joint Conference

*The Alcyone MEMS Cannula (AMC™) System, a neuro-ventricular cannula, has US Food and Drug Administration (FDA) 510(k) clearance, Health Canada Licensing, and CE Marking. It is indicated for use in the U.S. and Canada for the injection of Cytarabine or the removal of cerebrospinal fluid from the ventricles of the brain during an intracranial procedure, and approved in Europe for injection or removal of substances from the brain and/or ventricles of the brain during intracranial procedures. The AMC is a dual-lumen, MR-compatible injection and aspiration cannula and can be used with existing commercial imaging and stereotactic systems. The AMC is not intended for implant, and it is intended for single patient use only.

** The Pulsar System is not yet available for commercial use and has not yet been cleared by the FDA.